tradingkey.logo
搜索

Fulgent Genetics Inc

FLGT
添加自选
21.550USD
+0.280+1.32%
收盘 09-24 16:00(美东)
612.02M总市值
亏损市盈率 TTM

关于 Fulgent Genetics Inc 公司

Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.

Fulgent Genetics Inc 简介

公司代码FLGT
公司名称Fulgent Genetics Inc
上市日期Sep 28, 2016
CEOHsieh (Ming)
员工数量1313
证券类型Ordinary Share
年结日Sep 28
公司地址4399 Santa Anita Ave
城市EL MONTE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编91731
电话16263500537
网址https://www.fulgentgenetics.com/
公司代码FLGT
上市日期Sep 28, 2016
CEOHsieh (Ming)

Fulgent Genetics Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Ming Hsieh
Mr. Ming Hsieh
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.86M
-0.05%
Mr. Ming Hsieh
Mr. Ming Hsieh
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.86M
-0.05%
Mr. Ming Hsieh
Mr. Ming Hsieh
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.86M
-0.05%
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Chief Scientific Officer, Laboratory Director
Chief Scientific Officer, Laboratory Director
922.51K
-0.18%
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Chief Scientific Officer, Laboratory Director
Chief Scientific Officer, Laboratory Director
922.51K
-0.18%
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Chief Scientific Officer, Laboratory Director
Chief Scientific Officer, Laboratory Director
922.51K
-0.18%
Mr. Paul Kim, CPA
Mr. Paul Kim, CPA
Chief Financial Officer
Chief Financial Officer
280.01K
-0.75%
Mr. Paul Kim, CPA
Mr. Paul Kim, CPA
Chief Financial Officer
Chief Financial Officer
280.01K
-0.75%
Mr. Paul Kim, CPA
Mr. Paul Kim, CPA
Chief Financial Officer
Chief Financial Officer
280.01K
-0.75%
Mr. Jian (James) Xie
Mr. Jian (James) Xie
President, Chief Operating Officer
President, Chief Operating Officer
275.26K
-0.77%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Ming Hsieh
Mr. Ming Hsieh
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.86M
-0.05%
Mr. Ming Hsieh
Mr. Ming Hsieh
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.86M
-0.05%
Mr. Ming Hsieh
Mr. Ming Hsieh
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.86M
-0.05%
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Chief Scientific Officer, Laboratory Director
Chief Scientific Officer, Laboratory Director
922.51K
-0.18%
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Chief Scientific Officer, Laboratory Director
Chief Scientific Officer, Laboratory Director
922.51K
-0.18%
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Chief Scientific Officer, Laboratory Director
Chief Scientific Officer, Laboratory Director
922.51K
-0.18%

常见问题

Fulgent Genetics Inc的前五大股东是谁?

Fulgent Genetics Inc 的前五大股东如下:Mr. Ming Hsieh

有多少机构持有Fulgent Genetics Inc(FLGT)的股份?

截至2026Q1,共有430家机构持有Fulgent Genetics Inc的股份,合计持有的股份价值约为18.21M,占公司总股份的64.11%。与2025Q4相比,机构持股有所增加,增幅为-1416587.00。

哪个业务部门对Fulgent Genetics Inc的收入贡献最大?

在2026Q1,Insurance业务部门对Fulgent Genetics Inc的收入贡献最大,创收44.23M,占总收入的51.80%。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有